secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vogenx, Inc. (VOGX)
CIK:        0001903784
Form:       8-K
Filed at:   2026-10-09T17:30:37+00:00
Accession:  0001185185-26-004679
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Vogenx taps board member Richard Gorman as Chief Commercial Officer, effective Oct 12
--------------------------------------------------------------------------------

- Richard Gorman, an independent Vogenx director since 2022, becomes Chief Commercial Officer effective October 12, 2026, a newly created role.
- Gorman resigned from the Board and its Audit, Compensation and Nominating/Corporate Governance committees effective Oct 12; no disagreement with the company cited.
- He will lead commercial operations and corporate strategy, including market development for post-bariatric hypoglycemia and gastroparesis, plus business development and licensing.
- Vogenx will search for a new independent director to fill the board seat; CEO James Green credited Gorman with shaping strategy through the August 2026 IPO.
- Company says the hire supports advancing mizagliflozin into later-stage development; Gorman has 30 years of biopharma commercial experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1903784/000118518526004679/0001185185-26-004679-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1903784/000118518526004679/vogenx8k100826.htm
  HTML page:      https://secwatch.observer/filing/0001185185-26-004679

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer